Eversheds Sutherland has advised Peptonic
June 26, 2024
Eversheds Sutherland has advised PeptonicJune 26, 2024 Eversheds Sutherland advised Peptonic Medical AB ("Peptonic") on its SEK 61.4 million rights issue of units. Peptonic is a biomedical company engaged in the research and development of pharmaceuticals and medical devices in the field of women's health. The company's vision is to provide treatments for women's health and medical conditions. The company develops hormone-free products for the treatment of vaginal atrophy and vaginal dryness. The company has its headquarters in Sweden. Eversheds Sutherland’s team consisted of Mark Falkner, John Edgren and Hanna Ullerholt. Mangold Fondkommission AB acted as financial advisor to Peptonic. Latest News
Latest Eventsfirm news June 15, 2026 Eversheds Sutherland continues European expansion with further strategic pa... client news June 09, 2026 Eversheds Sutherland powers 12 key deals for Gresham House Energy Storage F... client news June 04, 2026 Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transi... client news June 04, 2026 Advising Howden Joinery Group plc on £390m DIY Kitchens acquisition |